Replies to post #34287 on Humanigen Inc (HGENQ)

[OneDay4488]

So the mistakes was believing in HGEN while Insiders were selling? You are correct it was a mistake

[cowtown jay]

Since none of us know how this will play out: not management; not shareholders; not analysts; not the manipulators; and not the regulators, all we are left with is our knowledge, gained by studying the science, our evaluation of the character and competence of the management team, and our view of lenzilumab's potential, compared to vaccines and other therapeutics, as well as what we see as the fear of this infection, and the responses to it, manifests throughout the world.

The Breaking News Presentations Durrant has been presenting says the following.

"Exploratory analysis of LIVE-AIR results in patients with CRP<150 mg/L and aged <85 years of age, which represented 74% of patients with an evaluable CRP at baseline, show lenzilumab improved the likelihood of survival without ventilation by more than 3-fold (OR 3.04; 95% CI: 1.68-5.51, nominal p=0.0003) compared with placebo and mortality was improved by more than 2-fold (OR: 2.22; 95%CI: 1.07-4.67, p=0.034)."

https://www.businesswire.com/news/home/20211019005646/en/Humanigen-Announces-Late-Breaking-Presentation-at-the-CHEST-Annual-Meeting-Highlighting-C-Reactive-Protein-as-a-Biomarker-for-Identifying-Patients-Most-Likely-to-Benefit-from-treatment-with-Lenzilumab

That should mean lights out for many of the approved and pending Covid products, perhaps including multiple vaccinations. I have not seen any results from competitive products that are even half as efficacious.

That's been reported to the FDA, with whom we have a Type B meeting scheduled next month to discuss these results. These results should be evident in the ongoing NIH trial, and I hope we are only allowing Clinigen to provide access to patients who meet our CRP limit of <150 mg/L, and those patients should also reflect what our trial investigators have observed. A peer review has been submitted for publication, and I hope competitors have not interfered with the publisher in this regard.

Frankly, I'm surprised the NIH hasn't recommended our approval, based on their expanded trial results, so the NIH can claim the victory.

If all else fails, we will be generating revenue through Clinigen, until we see a regulatory approval from Asia-Pacific or wherever it comes from.

So I don't think anything is more effective than lenz, and I see management doing everything they can to secure our success. There's literally nothing more I could ask.